首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation.
【24h】

Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation.

机译:在5,717例乳腺癌患者中,保守手术和乳房照射后的结果:锁骨上淋巴结转移的意义。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To evaluate the outcome and predictive factors of patients who underwent breast-conserving surgery and adjuvant radiotherapy to the whole breast only, without supraclavicular nodal irradiation. METHODS AND MATERIALS: A total of 5,717 patients with pT1-T4 breast cancer were treated at the University of Florence. The median age of the patient population was 55 years (range, 30-80 years). All patients were followed for a median of 6.8 years (range, 1-27 years). Adjuvant chemotherapy was recommended in 1,535 patients (26.9%). Tamoxifen was prescribed in 2,951 patients (51.6%). The patients were split into three groups according to number of positive axillary nodes (PAN): P1, negative axillary lymph nodes; P2, one to three PAN; P3, more than three PAN. RESULTS: The P3 patients had a higher incidence of supraclavicular fossa recurrence (SFR) compared with P2 and P1 patients. However, the incidence of SFR in P3 patients was low (only 5.5%), whereas the incidence of distant metastases (DM) was 27.2%. Distant metastasis was the only independent prognostic factor for breast cancer survival. Additionally, in the subgroup of patients who developed local recurrence, DM was the most important death predictor. CONCLUSION: Our series suggests that isolated SFR in patients who did not receive supraclavicular radiotherapy is infrequent, as well as in those patients who have more than three PAN, and SFR seems not to influence the outcome, which depends on DM occurrence.
机译:目的:评估未行锁骨上淋巴结照射而仅行全乳房保乳手术和辅助放疗的患者的结局和预测因素。方法和材料:佛罗伦萨大学共治疗了5717例pT1-T4乳腺癌患者。患者人群的中位年龄为55岁(范围为30-80岁)。所有患者的中位随访时间为6.8年(1-27年)。建议在1,535例患者中进行辅助化疗(26.9%)。在2,951例患者中开具了他莫昔芬处方(51.6%)。根据腋窝淋巴结阳性的数量将患者分为三组:P1,腋窝淋巴结阴性; P2,一到三个PAN; P3,三个以上的PAN。结果:与P2和P1患者相比,P3患者的锁骨上窝复发(SFR)发生率更高。然而,P3患者的SFR发生率较低(仅为5.5%),而远处转移(DM)的发生率为27.2%。远处转移是乳腺癌生存的唯一独立预后因素。此外,在发生局部复发的患者亚组中,DM是最重要的死亡预测因子。结论:我们的系列表明,未接受锁骨上放射疗法的患者以及有超过三个PAN的患者很少发生孤立SFR,SFR似乎不影响结局,这取决于DM的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号